Wechselwirkungen · Hepcludex
HEPCLUDEX 2 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-142397 · Präparat HOS-098824
In vitro an inhibition of OATP1B1/3 transporters by bulevirtide was observed, albeit only at a concentration ≥ 0.5 µM, which is only reached in vivo after administration of high bulevirtide doses (10 mg subcutaneous). The clinical relevance of these findings is unknown. As a precautionary measure, close clinical monitoring is warranted when OATP1B1/3 substrates (e.g. atorvastatin, bosentan, docetaxel, fexofenadine, glecaprevir, glyburide (glibenclamide), grazoprevir, nateglinide, paclitaxel, paritaprevir, pitavastatin, pravastatin, repaglinide, rosuvastatin, simeprevir, simvastatin, olmesartan, telmisartan, valsartan, voxilaprevir) are co-administered. When possible, co- administration of these substrates should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fexofenadine (HOS-086255) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) olmesartan (HOS-112363) docetaxel (HOS-084505) glyburide (HOS-109273) voxilaprevir (HOS-108930) grazoprevir (HOS-108815) simeprevir (HOS-086302) telmisartan (HOS-085187) paclitaxel (HOS-087959) valsartan (HOS-088810) nateglinide (HOS-089675) bosentan (HOS-086291) paritaprevir (HOS-110301) repaglinide (HOS-086935) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-31T10:15:00Z · SHA-256 56ea5f48399773f9051c5a5cc519d740db7ee3cdff519ad40c96b180c39a4a0f · Passage e4ef1700e52190dc95fda7461e5b1ebeb8be97d2217f6773b4c102817dc6b0b5 · Zeichen 663–1396 im Abschnitt